ReviewFrontiers in pharmacology2016
Drug Discovery via Human-Derived Stem Cell Organoids.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Latest Advanced Techniques for Improving Intestinal Organoids Limitations.Stem cell reviews and reports · 2025Review
- Microfluidics as a promising technology for personalized medicine.BioImpacts : BI · 2025Review
- Stem cell modeling of nervous system tumors.Disease models & mechanisms · 2024Review
- Advances in the Study of Common and RareJournal of personalized medicine · 2024Review
- Potential Application of Intestinal Organoids in Intestinal Diseases.Stem cell reviews and reports · 2024Review
- Assessment of source material for human intestinal organoid culture for research and clinical use.BMC research notes · 2022Article
- Patient-Derived Organoids for Precision Cancer Immunotherapy.Cancer research · 2021Review
- Organoids and Colorectal Cancer.Cancers · 2021Review
- Winter is coming: the future of cryopreservation.BMC biology · 2021Review
- Current Trends and Research Topics Regarding Intestinal Organoids: An Overview Based on Bibliometrics.Frontiers in cell and developmental biology · 2021Review
- Adipose-Derived Mesenchymal Stromal Cells in Regenerative Medicine: State of Play, Current Clinical Trials, and Future Prospects.Advances in wound care · 2021Review
- Organoids in Translational Oncology.Journal of clinical medicine · 2020Review
- Organoid technology in female reproductive biomedicine.Reproductive biology and endocrinology : RB&E · 2020Review
- Article
- Bioengineering NovelFrontiers in bioengineering and biotechnology · 2020Article
- Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.Marine drugs · 2019Article
- Layer-By-Layer: The Case for 3D Bioprinting Neurons to Create Patient-Specific Epilepsy Models.Materials (Basel, Switzerland) · 2019Review
- The pathogenesis of mucositis: updated perspectives and emerging targets.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Review
- Vitamin C and BJournal of biomedical materials research. Part A · 2019Article
- Morphophenotypic classification of tumor organoids as an indicator of drug exposure and penetration potential.PLoS computational biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-derived cell lines and animal models have proven invaluable for the understanding of human intestinal diseases and for drug development although both inherently comprise disadvantages and caveats. Many genetically determined intestinal diseases occur in specific tissue microenvironments that are not adequately modeled by monolayer cell culture. Likewise, animal models incompletely recapitulate the complex pathologies of intestinal diseases of humans and fall short in predicting the effects of candidate drugs. Patient-derived stem cell organoids are new and effective models for the development of novel targeted therapies. With the use of intestinal organoids from patients with inherited diseases, the potency and toxicity of drug candidates can be evaluated better. Moreover, owing to the novel clustered regularly interspaced short palindromic repeats/CRISPR-associated protein-9 genome-editing technologies, researchers can use organoids to precisely modulate human genetic status and identify pathogenesis-related genes of intestinal diseases. Therefore, here we discuss how patient-derived organoids should be grown and how advanced genome-editing tools may be applied to research on modeling of cancer and infectious diseases. We also highlight practical applications of organoids ranging from basic studies to drug screening and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.